Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial

Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor-based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference in incident hypertension (12% in each arm, P = .868) or change in blood pressure over the 48-week study period.